Description

Novanta’s Riverpoint Breakthrough Nearly Doubles Recurring Medical Revenue!

Novanta Incorporated reported solid financial and operational progress in the second quarter of 2026, marked by organic growth acceleration, strategic acquisition, and manufacturing optimization. The company achieved 9% organic sales growth and 10% reported growth, with adjusted EBITDA increasing 16% year-over-year and adjusted gross margin improving by 100 basis points to 47%. Adjusted earnings per share advanced 17%, and operating cash flow for the first half of the year surpassed that of all 2025. All four business units contributed to growth, supported by rising bookings and backlog. A key highlight was the completion of Novanta’s largest acquisition to date—Riverpoint Medical—which closed at the end of July and is expected to nearly double the recurring medical consumables business from approximately $150 million to $300 million annually.